Relmada Therapeutics Inc

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Relmada Therapeutics addresses setbacks, remains confident in REL-1017's potential

Relmada Therapeutics faced challenges in Q4 2022 with study results, leading to increased expenses and a net loss. Despite setbacks, the company remains confident in REL-1017's potential and is focused on refining trial protocols for future success.

Relmada Therapeutics reports positive Q1 results and advances MDD treatment

Relmada Therapeutics Inc. demonstrates financial improvement and progress in its REL-1017 program for major depressive disorder. The company's strategic amendments to study protocols and upcoming safety study data release indicate a commitment to advancing its pipeline. Addressing challenges in trial management and regulatory interactions is key to sustaining growth and market success.

Relmada Therapeutics reports improved Q2 financials and advances in key trials

Relmada Therapeutics showcased improved financial performance and progress in key clinical trials during the Q2 2023 Earnings Call.
While challenges like enrollment progress and regulatory feedback exist, the company's adaptability and cash position provide strengths to navigate them.
Opportunities lie in expanding the clinical program, achieving positive trial outcomes, and enhancing investor confidence through transparent communication.

Relmada Therapeutics reports positive Q3 results and advances key programs

Relmada Therapeutics demonstrated strong performance in Q3 2023 with progress in key programs and improved financial metrics.
While facing challenges in expense management and trial timelines, the company's strengths in research and financial discipline position them well for future growth.
Opportunities lie in leveraging positive trial results, attracting investors, and advancing innovative treatments to drive value creation.

Relmada Therapeutics reports progress in Phase III programs and financial stability

Relmada Therapeutics Inc showcased positive performance in its Phase III program and financial results, demonstrating resilience and strategic planning. While challenges exist in enrollment and monitoring, the company's confidence in its products and innovative approach to psilocybin present promising opportunities for growth and development.

Relmada Therapeutics Inc reports strong Q1 performance and pipeline advancements

Relmada Therapeutics Inc reported positive financial performance, progress in key programs, and proactive pipeline expansion in Q1 2024, positioning the company for future growth.
While facing challenges such as increased screening failure rates and competition, Relmada's strategic focus on trial optimization and therapeutic innovation presents opportunities for advancement.
The company's commitment to addressing mental health needs through Phase III trials and novel programs like psilocybin underscores its dedication to driving clinical progress and market differentiation.
With a strong financial position and promising developments in the pipeline, Relmada is poised to navigate challenges, capitalize on opportunities, and drive value for stakeholders.

Relmada Therapeutics advances CNS disorder treatments amidst financial stability

Relmada Therapeutics is making strides in advancing treatments for CNS disorders, with a focus on major depressive disorder. Financially, the company is managing expenses while progressing key programs. Uncertainty around interim analysis outcomes presents challenges, but successful results could open doors to new opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Relmada Therapeutics, Inc. (RLMD) CEO Sergio Traversa on Q4 2021 Results - Earnings Call Transcript

CORAL GABLES, Fla., March 23, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the fourth quarter and full year ended December 31, 2021.

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results

CORAL GABLES, Fla., March 16, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2021 after the market close on Wednesday, March 23, 2022.

Relmada Therapeutics to Report Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 23, 2022

CORAL GABLES, Fla., March 10, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in fireside chats at Needham & Company's 1st Annual Neuroscience Forum and Oppenheimer's 32nd Annual Healthcare Conference, taking place March 16th, 2022 at 9:30am ET and March 17th, 2022 at 1:20pm ET, respectively.

Relmada Therapeutics to Participate in Fireside Chats at Two Upcoming Healthcare Events

Relmada Therapeutics Inc (NASDAQ: RLMD) has announced topline results of the human abuse potential (HAP) study with REL-1017 for major depressive disorder or MDD. REL-1017 is a novel NMDA receptor (NMDAR) channel blocker and the Company's lead candidate.

Relmada Aces REL-1017 Vs Ketamine Study For Abuse Potential

CORAL GABLES, Fla., Feb. 23, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced top-line results of the human abuse potential (HAP) study with REL-1017, a novel NMDA receptor (NMDAR) channel blocker and the company's lead candidate in Phase 3 development for the treatment major depressive disorder (MDD).

Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Ketamine for Abuse Potential

CORAL GABLES, Fla., Feb. 10, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 8:00am Eastern Time.

Relmada Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

RLMD is set to produce results in 2022 from four clinical trials of REL-1017, its novel antidepressant. Late-stage failures of antidepressants are not unheard of, so I provide a cautionary tale to RLMD longs.

4 Clinical Catalysts On Tap For Relmada In 2022

The mean of analysts' price targets for Relmada Therapeutics, Inc. (RLMD) points to a 231.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 231% Upside in Relmada Therapeutics, Inc. (RLMD): Can the Stock Really Move This High?

CRISPR Therapeutics

Ultragenyx Pharmaceutical

Viking Therapeutics

Marinus Pharmaceuticals

For years, one of the most dependable sectors, especially for investors who are more conservative, was health care.

5 Sizzling ‘Strong Buy' Analyst Biotechnology Picks for 2022

CORAL GABLES, Fla., Dec. 22, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the publication of Phase 2 data from the clinical study of REL-1017 as adjunctive treatment for patients with major depressive disorder (MDD) in the peer-reviewed American Journal of Psychiatry, the most widely read psychiatric journal in the world.

Relmada Therapeutics Announces Publication of REL-1017 Phase 2 Study Results in The American Journal of Psychiatry

CORAL GABLES, Fla., Dec. 14, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the closing of a previously announced upsized underwritten public offering of 10,147,059 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,323,529 additional shares of common stock, at a public offering price of $17.00 per share.

Relmada Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option

Relmada Therapeutics Inc (NASDAQ: RLMD) priced an upsized underwritten public offering of 8.82 million shares at $17.00 per share, with gross proceeds of approximately $150 million.  The offer price represents a discount of almost 8% from the last close price of $18.54 on Wednesday.

Relmada Stock Falls After Equity Raise Of $150M To Fund Depression Candidate

CORAL GABLES, Fla., Dec. 8, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the pricing of an upsized underwritten public offering of 8,823,530 shares of its common stock at a public offering price of $17.00 per share.

Relmada Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

CORAL GABLES, Fla., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced its intention to offer and sell $100 million of shares of its common stock in an underwritten public offering pursuant to its existing shelf registration statement. Relmada also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the size or terms of the offering.

Relmada Therapeutics Announces Proposed Public Offering of Common Stock

CORAL GABLES, Fla., Dec. 1, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today that the data related to the recently completed human abuse potential (HAP) study evaluating REL-1017—the company's lead product candidate—versus oxycodone, will be presented in a poster presentation at the 60th Annual Meeting of the American College of Neuropsychopharmacology, which is taking place December 5-8, 2021, in San Juan, Puerto Rico.

Relmada Therapeutics to Present Data at the 60th Annual Meeting of the American College of Neuropsychopharmacology

Relmada Therapeutics, Inc. (RLMD) CEO Sergio Traversa on Q3 2021 Results - Earnings Call Transcript

CORAL GABLES, Fla., Nov. 11, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced financial results for the three and nine months ended September 30, 2021.

Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results

CORAL GABLES, Fla., Nov. 9, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will present at the Jefferies London Healthcare Conference on November 17 th, 2021 at 8:00am Eastern Time.

Relmada Therapeutics to Present at the Jefferies London Healthcare Conference

CORAL GABLES, Fla., Nov. 4, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter and nine months ended September 30, 2021 after the market close on Thursday, November 11, 2021.

Relmada Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 11, 2021

CORAL GABLES, Fla., Oct. 29, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that data related to REL-1017, the company's lead product candidate, will be presented in eight poster presentations at the Neuroscience Education Institute (NEI) Congress.

Relmada Therapeutics to Present Data at the Neuroscience Education Institute Congress

CORAL GABLES, Fla., Oct. 4, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided regulatory and development updates regarding its ongoing late-stage clinical program for REL-1017 in major depressive disorder (MDD).

Relmada Therapeutics Provides Regulatory and Development Updates on Ongoing Late-Stage Clinical Program for REL-1017 for Treatment of Major Depressive Disorder

CORAL GABLES, Fla., Sept. 17, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer of Relmada, will present at the annual Oppenheimer Fall Healthcare Life Sciences and MedTech Summit, on September 21, 2021, at 12:25 pm ET.

Relmada Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

CORAL GABLES, Fla., Sept. 3, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer of Relmada, will present at the 19th Annual Morgan Stanley Global Healthcare Conference, on September 10, 2021, at 12:30 pm Eastern Time.

Relmada Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

Relmada Therapeutics, Inc. (RLMD) CEO Sergio Traversa on Q2 2021 Results - Earnings Call Transcript

News for Relmada Therapeutics Inc Stock (RLMD)